Experiment | Group | n | SA Day 1, infusions ± SE | SA Day 14, infusions ± SE | Total intake, net mg/kg ± SE | First Ext, responses ± SE | Last Ext, responses ± SE | Days to Ext ± SE |
---|---|---|---|---|---|---|---|---|
1 | Sal/No Shock | 9 | 5.2 ± 1.2 | 1.5 ± 0.2 | 0 | 5.4 ± 1.0 | 5.0 ± 1.0 | 11.1 ± 0.6 |
Sal/Shock | 9 | 3.7 ± 0.9 | 2.4 ± 0.6 | 0 | 5.0 ± 1.9 | 4.8 ± 0.8 | 11.9 ± 1.3 | |
ShA/No Shock | 7 | 24.0 ± 3.2 | 21.6 ± 4.8 | 71.0 ± 4.0 | 73.8 ± 15.2 | 9.4 ± 2.8 | 12.8 ± 0.9 | |
Sha/Shock | 6 | 26.6 ± 1.3 | 21.4 ± 5.1 | 67.4 ± 3.6 | 45.2 ± 13.8 | 5.1 ± 1.4 | 10.8 ± 0.2 | |
LgA/No Shock | 6 | 82.1 ± 3.9 | 96.9 ± 2.3 | 243.7 ± 6.2 | 36.0 ± 11.0 | 11.7 ± 2.3 | 14.0 ± 1.5 | |
LgA/Shock | 10 | 77.7 ± 4.2 | 90.9 ± 6.2 | 225.6 ± 13.9 | 42.7 ± 11.9 | 11.5 ± 3.0 | 13.2 ± 1.3 | |
2 | No Shock | 5 | 63.5 ± 15.2 | 91.2 ± 0.9 | 210.3 ± 14.2 | 45.8 ± 12.8 | 7.0 ± 5.3 | 10.4 ± 1.4 |
Shock | 6 | 71.5 ± 7.3 | 88.0 ± 4.3 | 218.4 ± 26.3 | 34.8 ± 7.5 | 10.0 ± 2.0 | 9.5 ± 2.1 | |
3 | hM4Di | 7 | 64.0 ± 5.1 | 78.0 ± 8.7 | 202.8 ± 9.2 | 32.2 ± 3.5 | 11.3 ± 1.9 | 18.0 ± 5.2 |
Control | 6 | 71.5 ± 4.0 | 80.9 ± 5.0 | 209.3 ± 8.0 | 43.5 ± 4.3 | 9.0 ± 2.0 | 11.9 ± 1.5 | |
4 | Veh/No Shock | 5 | 83.6 ± 4.3 | 91.6 ± 6.3 | 212.9 ± 27.6 | 67.3 ± 18.3 | 8.0 ± 1.8 | 8.5 ± 0.5 |
Veh/Shock | 5 | 65.0 ± 12.3 | 94.0 ± 4.9 | 218.5 ± 21.5 | 54.5 ± 14.3 | 8.0 ± 1.8 | 6.3 ± 0.8 | |
Ant/No Shock | 5 | 78.0 ± 9.0 | 105.1 ± 11.2 | 233.0 ± 37.5 | 56.7 ± 20.3 | 6.8 ± 2.4 | 6.7 ± 0.5 | |
Ant/Shock | 5 | 80.6 ± 4.6 | 100.2 ± 7.5 | 222.1 ± 25.3 | 92.2 ± 21.3 | 8.0 ± 2.8 | 5.3 ± 0.2 | |
5 | PL/VTA Contra | 7 | 61.9 ± 8.3 | 80.7 ± 6.9 | 179.8 ± 11.8 | 43.3 ± 9.2 | 6.7 ± 1.6 | 9.4 ± 1.7 |
PL/VTA Ipsi | 7 | 62.9 ± 8.9 | 79.7 ± 8.7 | 199.9 ± 13.0 | 67.0 ± 15.5 | 10.7 ± 1.6 | 9.9 ± 1.7 | |
IL/VTA Contra | 5 | 73.0 ± 6.2 | 82.0 ± 7.2 | 209.6 ± 20.3 | 70.0 ± 37.6 | 8.8 ± 2.3 | 11.8 ± 1.8 | |
6 | Sal | 8 | 3.6 ± 0.8 | 3.3 ± 1.8 | 0 | 4.5 ± 1.3 | 3.2 ± 0.9 | 10 |
ShA | 8 | 28.7 ± 2.6 | 21.2 ± 4.0 | 70.0 ± 7.7 | 46.3 ± 10.0 | 26.7 ± 7.7 | 10 | |
LgA | 8 | 67.4 ± 7.8 | 85.10.6 ± 8.6 | 211.1 ± 13.3 | 51.0 ± 15.7 | 20.2 ± 6.6 | 10 |
Data represent cocaine SA by rats in each experiment, expressed as the numbers of infusions/session on Days 1 and 14 during the SA test period and total cocaine intake (mg/kg) across the 14 d period, responding (lever presses) during the first and last extinction session prior to reinstatement testing and the number of sessions required to meet the extinction criterion for each experiment. All data represent mean ± SE. The final sample size (n) for each experiment is also listed. PL, Prelimbic cortex; IL, intralimbic cortex.